Low PAPP-A: what are the clinical implications?

Abstract
Ultrasound and pulsed Doppler can assist in confirming impaired placentation looking at fetal biometry and umbilical artery Dopplers. The authors recommend confirmation of fetal wellbeing at 28–30 weeks with a PAPP-A level below the first centile.

Keywords: maternal serum, PAPP-A.

Introduction
Recent evidence has shown that low levels of Pregnancy-associated plasma protein A (PAPP-A) at the first trimester screening test can be an independent risk factor for certain adverse pregnancy outcomes such as intrauterine fetal death after 24 weeks, spontaneous fetal loss before 24 weeks, preterm birth, gestational hypertension, preeclampsia and low birth weight.1–5

It remains unclear however, if low serum PAPP-A levels should be used as a screening tool for adverse outcomes, and if so, what cut-off values should be used? Data suggest the positive predictive values for the individual outcomes and sensitivity is low, reducing the value as a screening test, despite reports of statistically significant associations.

In this case review, two women presented to our maternity unit in the same week with very similar first trimester serum PAPP-A levels (<1st percentile) but had entirely different clinical outcomes.

The first woman had an uncomplicated but anxious antenatal course, satisfactory growth ultrasounds at 30 and 38 weeks gestation and a healthy birth after an induction of labour (patient request) at 39 weeks. The second patient presented with a massive placental abruption at 34 weeks, requiring an emergency caesarean section. The baby was stillborn with severe intrauterine growth restriction. This woman was a smoker, poorly compliant, with a previous history of IUGR and preeclampsia.

PAPP-A is a large zinc glycoprotein produced by placental trophoblasts, particularly the extravillous cytotrophoblasts.6 It belongs to the alpha-macroglobulin plasma protein group and is a metalloproteinase (enzyme that specifically cleaves proteins). It can connect to a range of cytokines and modulates their activity.6 Haaning, et al. discovered that full-length pre PAPP-A contains over 1500 amino acids.7

PAPP-A molecules tend to cleave insulin-like growth factor (IGF) binding proteins 4 and 5.8 This means it can help release IGF from these binding proteins enabling it to interact with its cell receptor.7 It is suggested that IGF has a critical role in trophoblast invasion, affecting early development and vascularisation of the placenta and the placental bed.8

Maternal serum PAPP-A levels are first detected around 28 days post implantation. This is often followed by a rapid rise (levels doubling every 3–4 days) and then a gradual increase until term.9

PAPP-A is found in the ovarian follicles, luteal cells and fallopian tubes of non-pregnant women. In men it is present in seminal fluid. PAPP-A is present in unstable atherosclerotic plaques circulating levels are elevated in acute coronary syndromes.10

Serum PAPP-A levels are significantly reduced in pregnancies conceived with assisted reproductive techniques (ART). A recent study by Amor, et al. reported average PAPP-A multiples of the median (MoM) of 0.83 in these women vs. 1.00 MoM for spontaneous conceptions. The authors suggested that the low PAPP-A levels could be because of a less than optimal early implantation process in some forms of ART.11

Westergaard, et al. reported complete absence of PAPP-A in both maternal blood and placental tissue from a pregnancy with Cornelia de Lange syndrome.12 Serum PAPP-A has been used in combination with free beta human chorionic gonadotropin (B-hCG) and nuchal translucency as an effective first-trimester screening marker for pregnancies including trisomies 13, 18, and 21. Nicolaides reported that the combination of first trimester serum biochemical analyses with nuchal translucency measurements detected about 90% of fetuses with Down syndrome with a false positive rate of 5%. It can be further improved by the inclusion of other ultrasound makers (like the presence nasal bone) and Doppler parameters. This, in combination with early biochemical testing around 9–10 weeks can improve detection rates of Trisomy 21 up to 94%.13,14

The well known
Aneuploidies have each a specific biochemical pattern.

Data from the First and Second Trimester Evaluation of Risk for Fetal Aneuploidy (FASTER) trial11 reported an association between low PAPP-A levels (≤ 5th percentile) and significantly higher rates of spontaneous fetal loss ≤ 24 weeks, preeclampsia, low birth weight and preterm birth. A multicentre, prospective cohort study of 7934 women found that most of the increase in risk of stillbirth was attributed to placental dysfunction associated with placental abruption or intrauterine growth restriction.1 The contrast in outcomes between the two women in our case study with similar PAPP-A levels illustrates how difficult it can be to predict adverse outcome because of a low PAPP-A alone. The important difference between the two pregnancies are the vastly different histories (smoking, previous IUGR, previous preeclampsia, poor socio-economic status) and should therefore always be taken into account when formalising a management plan. Consideration should be given to the possible need for other tests (e.g. thrombophilia screen) or interventions (e.g. low does aspirin).

What level of PAPP-A should be used to screen at risk women? PAPP-A levels of less than the fifth percentile were shown in some studies to have a high specificity but low positive predictive value for adverse pregnancy outcomes.15,16 The First Trimester Maternal Serum Biochemistry and Ultrasound Fetal Nuchal Translucency Study (BUN) found PAPP-A levels less than the 1st percentile had a high positive predictive value for IUGR.18 Therefore, it would be more appropriate to use a lower PAPP-A level for a more cost effective screening program for adverse pregnancy outcomes.17–19

Table 1: Serum PAPP-A MoM levels with population percentile.

| PAPP – A MoM | Percentile |
|--------------|------------|
| 0.45–2.07    | 5th – 95th |
| < 0.29       | < 1st      |
| < 0.44       | < 5th      |
| > 2.08       | > 95th     |
| > 3.92       | > 99th     |

Table 2: Clinical details. The two sides of the clinical coin increased anxiety during an otherwise low risk pregnancy versus an adverse outcome resulting in stillbirth.

| Case 1 | Case 2 |
|--------|--------|
| 38 yo  | 39 yo  |
| PAPP-A 0.27 MoM | PAPP-A 0.26 MoM |
| GSP3 (2.4, 2.8, 2.4 kg) | G2P1 (3.1kg) |
| BMI 28  | BMI 30 |
| Previous preeclampsia, Gestational Diabetes Mellitus | Uncomplicated pregnancy |
| Smoker  | Fetal anomaly scan – no abnormality detected |
| Poor antenatal compliance | 30 & 38wk USS satisfactory growth, no abnormality detected |
| 28 wk ultrasound – no abnormality detected | 39+1 wks Favourable cervix |
| EFW on 15th centile. Did not attend subsequent ultrasound as requested | Induction of labour for low PAPP-A (Patient anxiety/ request) |
| Antepartum Haemorrhage at 34/40, code 1 LSCS | 6 hr labour, live female infant, birth weight 3100 g |
| Stillborn male 1390 g | Newborn Nagars 9’ & 9’ |
| Postnatal thrombophilia screen -negative | |
| Desires further fertility | |

References
1. Handschuh K, Guibourdenche J, Guesnon M, Laurendeau I, Evain-Brion D, Fournier T. Modulation of PAPP-A expression by PPARalpha in human first trimester trophoblast. Placenta 2006; 27 Suppl A:S127–34.
2. Smith GC, Stenhousse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia and stillbirth. J Clin Endocrinol Metab 2002; 87: 1762–67.
3. Scott F, Coates A, McLennan A. Pregnancy outcome in the setting of extremely low first trimester PAPP-A levels. Aust N Z J Obstet Gynaecol 2009; 49: 258–62.
4. Spencer K, Cowans NJ, Avigdou K, Molina F, Nicolaides H. First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses. Ultrasound Obstet Gynecol 2008; 31: 15–19.
5. Barrett SL, Bower C, Hadlow N. Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes. Prenat Diag 2008; 28: 28–35.
6. Zhabin SG, Gorin VS, Judin NS. Review: immunomodulatory activity of pregnancy-associated plasma protein-A. J Clin Lab Immunol 2003; 52: 41–50.
7. Haaning J, Oxvig C, Overgaard MT, Ebbesen P, Kristensen T, Sottrup-Jensen L. Complete cDNA sequence of preproform of human pregnancy-associated plasma protein-A: evidence for expression in the brain and induction by cAMP. Eur J Biochem 1996; 237: 159–63.
8. Laursen LS, Kjaer-Sorensen K, Andersen MH, Oxvig C. Regulation of insulin-like growth factor (IGF) bioactivity by sequential proteolytic cleavage of IGF binding protein-4 and -5. Mol Endocrinol 2007; 21: 1246–57.

Conclusion
Biochemical markers like PAPP-A can be a useful tool to screen for impaired placentation associated with fetal growth restriction, fetal death in-utero, pre-eclampsia and abruptio placentae. Ultrasound and pulsed Doppler are diagnostic modalities that can assist in confirming impaired placentation looking at fetal biometry and umbilical artery Dopplers. We recommend confirmation of fetal wellbeing at 28–30 weeks with a serum PAPP-A level below the 1st centile.
9 Sinosisch MJ. Biological role of pregnancy-associated plasma protein-A in human reproduction. 158.183. In: Bischof P, Klooper A (Eds): Proteins of the Placenta. 5th International Congress on Placental Proteins, Annecy 1984. Karger, Basel, 1985.
10 Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR Jr, Virmani R, Oxvig C, Schwartz RS. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001; 345 (14): 1022–9.
11 Amor DJ, Xu JX, Halliday JL, Francis I, Healy DL, Breheny S, et al. Pregnancies conceived using assisted reproductive technologies (ART) have low levels of pregnancy-associated plasma protein-A (PAPP-A) leading to a high rate of false-positive results in first trimester screening for Down syndrome. Hum Reprod 2009; 24 (6): 1330–8.
12 Westergaard JG, Chemnitz J, Teisner B, Poulsen HK, Ipsen L, Beck B, et al. Pregnancy associated plasma protein A: a possible marker in the classification and prenatal diagnosis of Cornelia de Lange syndrome. Prenat Diagn 1983; 3: 225–32.
13 Nicolaides KH. Screening for fetal aneuploidies at 11–13 weeks. Prenat Diagn 2011; 31: 7–15.
14 Dugoff L, Hobbins JC, Malone FD, Porter TF, Lutdy D, Comstock CH, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: A population-based screening study (The FASTER Trial). Am J Obstet Gynecol 2004; 191: 1446–51.
15 Yaron Y, Heifetz A, Ochshorn Y, Lehavi O, Orr-Urttger A. Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat Diagn 2002; 22: 778–82.
16 Smith GC, Crossley JA, Aitken DA, Pell JP, Cameron AD, Connor JM, et al. First-trimester placentation and the risk of antepartum stillbirth. JAMA 2004; 292: 2249–54.
17 Kwik M, Morris J. Association between first trimester maternal serum pregnancy associated plasma protein-A and adverse pregnancy outcome. Aust N Z J Obstet Gynaecol 2003; 43: 438–42.
18 Krantz D, Goetzl L, Simpson JL, Thom E, Zachary J, Hallahan TW. Association of extreme first-trimester free human chorionic gonadotropin–beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 2004; 191: 1452–58.
19 Brameld KJ, Dickinson JE, O’Leary P, Bower C, Goldblatt J, Hewitt B, Murch A, et al. First trimester predictors of adverse pregnancy outcomes. Aust N Z J Obstet Gynaecol 2008; 48: 329–35.